Abstract
Although T cells were previously believed to recognize only peptide antigen associated with the major histocompatibility complex (MHC), recent studies have shown that there are unique T cells specialized for recognition of lipid or glycolipid antigens bound to the MHC class I-like CD1 molecules (CD1a, b, c or d). Among these lipid-specific T cells, CD1d-restricted T cells, also referred to as natural killer (NK) T cells, are of special interest as a target of drug development, since their role in immunoregulation has been indicated in various physiological or disease conditions including autoimmunity. They are unique in their homogeneous ligand specificity for α-glycosylated sphingolipid and secrete large amounts of regulatory cytokines shortly after T cell receptor (TCR) engagement. The first glycolipid identified as an NKT cell ligand was α-galactosylceramide (α-GalCer) derived from marine sponges. α-GalCer exhibits significant immunomodulatory effects by stimulating NKT cells. However, we found that an altered analogue of α-GalCer with a shorter sphingosine chain (OCH), is more useful than α-GalCer for treatment of autoimmune disease models, because of its ability to selectively induce IL-4, a key cytokine for control of autoimmunity. As such, altered glycolipid ligands (AGL) of α-GalCer appear to be promising reagents for treatment of human autoimmune diseases.
Keywords: NKT Cell-Stimulating Synthetic Glycolipids, sphingosine, autoimmunity
Current Topics in Medicinal Chemistry
Title: NKT Cell-Stimulating Synthetic Glycolipids as Potential Therapeutics for Autoimmune Disease
Volume: 4 Issue: 5
Author(s): Takashi Yamamura, Katsuichi Miyamoto, Zsolt Illes, Endre Pal, Manabu Araki and Sachiko Miyake
Affiliation:
Keywords: NKT Cell-Stimulating Synthetic Glycolipids, sphingosine, autoimmunity
Abstract: Although T cells were previously believed to recognize only peptide antigen associated with the major histocompatibility complex (MHC), recent studies have shown that there are unique T cells specialized for recognition of lipid or glycolipid antigens bound to the MHC class I-like CD1 molecules (CD1a, b, c or d). Among these lipid-specific T cells, CD1d-restricted T cells, also referred to as natural killer (NK) T cells, are of special interest as a target of drug development, since their role in immunoregulation has been indicated in various physiological or disease conditions including autoimmunity. They are unique in their homogeneous ligand specificity for α-glycosylated sphingolipid and secrete large amounts of regulatory cytokines shortly after T cell receptor (TCR) engagement. The first glycolipid identified as an NKT cell ligand was α-galactosylceramide (α-GalCer) derived from marine sponges. α-GalCer exhibits significant immunomodulatory effects by stimulating NKT cells. However, we found that an altered analogue of α-GalCer with a shorter sphingosine chain (OCH), is more useful than α-GalCer for treatment of autoimmune disease models, because of its ability to selectively induce IL-4, a key cytokine for control of autoimmunity. As such, altered glycolipid ligands (AGL) of α-GalCer appear to be promising reagents for treatment of human autoimmune diseases.
Export Options
About this article
Cite this article as:
Yamamura Takashi, Miyamoto Katsuichi, Illes Zsolt, Pal Endre, Araki Manabu and Miyake Sachiko, NKT Cell-Stimulating Synthetic Glycolipids as Potential Therapeutics for Autoimmune Disease, Current Topics in Medicinal Chemistry 2004; 4 (5) . https://dx.doi.org/10.2174/1568026043451221
DOI https://dx.doi.org/10.2174/1568026043451221 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design Systemic Lupus Erythematosus and Other Autoimmune Diseases from Endogenous and Exogenous Agents: Unifying Theme of Oxidative Stress
Mini-Reviews in Medicinal Chemistry Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Leukocyte Function-Associated Antigen-1: Structure, Function and Application Prospects
Protein & Peptide Letters Directing an Appropriate Immune Response: The Role of Defense Collagens and other Soluble Pattern Recognition Molecules
Current Drug Targets Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents Computational Studies Applied to Anti-inflammatory Drug Discovery: A Review
Current Organic Chemistry Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Oxidized Human Beta2-Glycoprotein I: Its Impact on Innate Immune Cells
Current Molecular Medicine Generation and Characterization of a Functional Nanobody Against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?
Inflammation & Allergy - Drug Targets (Discontinued) Cough in Respiratory and Autoimmune Disorders
Current Respiratory Medicine Reviews Polypeptide Delivery Across The Blood-Brain Barrier
Current Drug Targets - CNS & Neurological Disorders